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Abstract
Introduction Our goal was to generate xenograft mouse models
of human breast cancer based on luciferase-expressing MDA-
MB-231 tumor cells that would provide rapid mammary tumor
growth; produce metastasis to clinically relevant tissues such as
lymph nodes, lung, and bone; and permit sensitive in vivo
detection of both primary and secondary tumor sites by
bioluminescent imaging.
Method Two clonal cell sublines of human MDA-MB-231 cells
that stably expressed firefly luciferase were isolated following
transfection of the parental cells with luciferase cDNA. Each
subline was passaged once or twice in vivo to enhance primary
tumor growth and to increase metastasis. The resulting
luciferase-expressing D3H1 and D3H2LN cells were analyzed
for long-term bioluminescent stability, primary tumor growth, and
distal metastasis to lymph nodes, lungs, bone and soft tissues
by bioluminescent imaging. Cells were injected into the
mammary fat pad of nude and nude-beige mice or were
delivered systemically via intracardiac injection. Metastasis was
also evaluated by ex vivo imaging and histologic analysis
postmortem.
Results The D3H1 and D3H2LN cell lines exhibited long-term
stable luciferase expression for up to 4–6 months of
accumulative tumor growth time in vivo. Bioluminescent imaging
quantified primary mammary fat pad tumor development and
detected early spontaneous lymph node metastasis in vivo.
Increased frequency of spontaneous lymph node metastasis
was observed with D3H2LN tumors as compared with D3H1
tumors. With postmortem ex vivo imaging, we detected
additional lung micrometastasis in mice with D3H2LN mammary
tumors. Subsequent histologic evaluation of tissue sections
from lymph nodes and lung lobes confirmed spontaneous tumor
metastasis at these sites. Following intracardiac injection of the
MDA-MB-231-luc tumor cells, early metastasis to skeletal
tissues, lymph nodes, brain and various visceral organs was
detected. Weekly in vivo imaging data permitted longitudinal
analysis of metastasis at multiple sites simultaneously. Ex vivo
imaging data from sampled tissues verified both skeletal and
multiple soft tissue tumor metastasis.
Conclusion This study characterized two new bioluminescent
MDA-MB-231-luc human breast carcinoma cell lines with
enhanced tumor growth and widespread metastasis in mice.
Their application to current xenograft models of breast cancer
offers rapid and highly sensitive detection options for preclinical
assessment of anticancer therapies in vivo.
Introduction
Development of breast cancer mouse models that provide
consistent primary mammary tumors and metastasis to clini-
cally relevant tissues such as lymph nodes, lungs, and bone
remain a challenge in the preclinical evaluation of therapies for
human breast cancer. Current xenograft models of breast car-
cinoma involve murine or human breast cancer cell lines
implanted into the mammary fat pad of mice or injected sys-
temically by intravenous or intracardiac routes. Tumor cells
injected into the mammary tissue yield reproducible tumors,
but can require weeks to several months for primary tumor
development and produce varied spontaneous metastasis
depending on the cell line and mouse strain used in the study
[1].
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One common human breast cancer cell line used in xenograft
animals models is MDA-MB-231. These cells originated from
a human metastatic ductal breast carcinoma sample [2], are
estrogen independent, and exhibit preferential growth in the
mammary fat pad of immune compromised mice [3]. MDA-MB-
231 cells develop primary tumors that produce spontaneous
metastasis to lymph nodes and micrometastases to the lungs
[4]. Detection of metastasis has relied primarily upon histolog-
ical or PCR analysis of selected tissues at experimental end-
points. Spontaneous metastasis to bone or soft organs from
primary mammary tumors has not been reported.
Reproducible bone metastasis in breast cancer xenograft
models has been achieved with intracardiac injection of MDA-
MB-231 cells [5,6]. Passaging tumor cells harvested from the
bone lesions several times in vivo has created MDA-MB-231
sublines with exclusive propensity for bone metastasis [7-10].
The bone metastases are typically identified in animals by radi-
ographic or histological procedures. Recently, researchers
have begun to apply luciferase-based imaging methods to
detect widespread metastasis in mouse breast cancer models
[10-13]. In studies using luciferase-expressing MDA-MB-231
tumor cell sublines specifically selected for skeletal metasta-
sis, in vivo imaging was able to monitor experimental bone
metastasis in mice to a level comparable to that of X-ray anal-
ysis [10,13]. Our goal was to develop a bioluminescent human
breast cancer cell line that would offer a similar level of detec-
tion for both primary and metastatic tumors and would more
fully mimic clinical breast cancer by metastasizing to multiple
tissues, including lymph nodes, lungs, bone, and visceral
organs.
This report describes bioluminescent xenograft mouse models
based on more widely metastatic derivatives of MDA-MB-231
cells. These two luciferase-expressing cell lines, D3H1 and
D3H2LN, were isolated for stable firefly luciferase expression
in vitro and were passaged in mice to enhance their tumori-
genic and metastatic properties. We evaluated the effect of
long-term in vivo growth on the stability of cellular biolumines-
cence. In vivo and ex vivo imaging was used to monitor and
compare the primary tumor growth rates and metastatic poten-
tial from mammary tumors and after intracardiac injection of
the two MDA-MB-231 sublines over time.
Materials and methods
Tumor cell line
Human breast cancer cell line MDA-MB-231 was obtained
from the American Type Culture Collection (Rockville, MA,
USA). Cells were cultured in Minimum Essential Medium with
Earl's Balanced Salts Solution MEM/EBSS medium supple-
mented with 10% fetal bovine serum, 1% nonessential amino
acids, 1% L-glutamine, and 1% sodium pyruvate (all from
Hyclone, Logan, UT, USA) at 37°C in a humidified atmosphere
containing 5% carbon dioxide.
Co-transfection and selection of cell line
MDA-MB-231 cells were co-transfected with plasmids
expressing the firefly luciferase gene (luc; pGL3-Red, Chris
Contag, Stanford University, Stanford, CA, USA) and zeocin
resistance gene (pSV40/Zeo; Invitrogen, Carlsbad, CA, USA)
using lipofectamine (Invitrogen). Transfected cells were then
selected for antibiotic resistance (zeocin; Invitrogen) and sur-
viving colonies were screened for bioluminescence in com-
plete media supplemented with 150 µg/ml D-luciferin
(Biosynth International, Inc, Naperville, IL, USA) by in vitro
imaging using the IVIS™ camera system (Xenogen, Alameda,
CA, USA; see below). Bioluminescent, antibiotic resistant, sin-
gle cell clones were amplified in culture and characterized for
stable luminescence in vitro and tumorigenic potential in vivo.
One clonal cell line, MDA-MB-231-luc-D3, was initially
selected. This D3 clone was passaged through mice as a pri-
mary tumor in the mammary fat pad to produce the D3H1 cell
line. A spontaneous lymph node metastasis from a D3H1
mammary fat pad tumor was also harvested and designated
D3H2LN. These three bioluminescent derivatives of MDA-MB-
231 cells were used for further in vitro or in vivo studies.
Bioluminescent imaging
Bioluminescent imaging was performed with a highly sensitive,
cooled CCD camera mounted in a light-tight specimen box
(IVIS™; Xenogen), using protocols similar to those described
previously [14-17]. Imaging and quantification of signals were
controlled by the acquisition and analysis software Living
Image® (Xenogen). For in vitro imaging, bioluminescent cells
were serially diluted from 4000 to 8 cells in complete media
into black, clear bottomed, 96-well plates (Costar, Acton, MA,
USA). D-luciferin (Biosynth International, Inc.) at 150 µg/ml in
media was added to each well 5–10 min before imaging.
Imaging time was 1 min/plate. For in vivo imaging, animals
were given the substrate D-luciferin by intraperitoneal injection
at 150 mg/kg in DPBS Dulbecco's Phosphate Buffered Saline
(Invitrogen, Carlsbad, CA, USA), and anesthetized (1–3% iso-
flurane). Mice were then placed onto the warmed stage inside
the light-tight camera box with continuous exposure to 1–2%
isoflurane. Imaging times ranged from 1 s to 3 min, depending
on the tumor model and time point. Generally, two to three
mice were imaged at a time. The low levels of light emitted
from the bioluminescent tumors or cells were detected by the
IVIS™ camera system, integrated, digitized, and displayed.
Regions of interest from displayed images were identified
around the tumor sites and were quantified as total photon
counts or photons/s using Living Image® software (Xenogen).
Background bioluminescence in vivo was in the region of 1 ×
104 photon counts or 1–2 × 105 photons/s. For ex vivo imag-
ing, 150 mg/kg D-luciferin was injected into the mice just
before necropsy. Tissues of interest were excised, placed into
24-well tissue culture plates with 300 µg/ml D-luciferin in
DPBS, and imaged for 1–2 min. Tissues were subsequently
fixed in 10% formalin (Sigma, St. Louis, MO, USA) and pre-
pared for standard histopathology evaluation.Available online http://breast-cancer-research.com/content/7/4/R444
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Mouse strain and animal care
Strict animal care procedures set forth by the Institutional Ani-
mal Care and Use Committee based on guidelines from the
US National Institutes of Health Guide for the Care and Use of
Laboratory Animals were followed for all experiments [18].
Mice used in these studies were either female athymic nude-
nu mice aged 8–10 weeks (Harlan, Indianapolis, IN, USA) or
female nude-beige (NIH-bg-nu-xidBR) mice aged 8–10 weeks
(Charles River Laboratories, Wilmington, MA, USA).
Mammary fat pad spontaneous metastasis model
Female nude mice or female nude-beige mice aged 8–10
weeks were anesthetized by exposure to 1–3% isoflurane and
injected with 50 µl of 2 × 106 MDA-MB-231 cells suspended
in 50% DPBS/50% matrigel into the abdominal mammary fat
pad. At 10–15 min after luciferin injection, mice were placed
in the IVIS™ Imaging System and imaged from the ventral view.
Tumor growth was monitored weekly by bioluminescent imag-
ing and external caliper measurements (tumor size = [length ×
width × height] × 0.52) for 5–9 weeks. In some experiments,
the lower portion of each animal was shielded before reimag-
ing in order to minimize the bioluminescence from the primary
tumor so that the signals from the metastatic regions could be
observed in vivo. The front limbs were secured with tape to
better expose the axillary/brachial lymph node areas. The
imaging time ranged from 1 s to 1 min, depending on the size
of the primary tumors, but was consistently 3 min for detection
of metastases.
Intracardiac experimental metastasis model
Female nude mice (age 8–10 weeks) were anesthetized by
intramuscular injection of 120 mg/kg ketamine hydrochloride
with 6 mg/kg xylazine on the day of injections, and by exposure
to 1–3% isoflurane on subsequent imaging days. On day 0,
anesthetized animals were injected with 1 × 105 MDA-MB-
231 cells suspended in 100 µl sterile DPBS into the left ven-
tricle of the heart by nonsurgical means [19]. Anesthetized
mice were placed in the IVIS™ Imaging System and imaged
from both dorsal and ventral views approximately 10–15 min
after intraperitoneal injection of D-luciferin. A successful int-
racardiac injection was indicated on day 0 by images showing
systemic bioluminescence distributed throughout the animal.
Only mice with evidence of a satisfactory injection continued
in the experiment. Assessment of subsequent metastasis was
monitored in vivo once a week by imaging for up to 5 weeks.
Histopathology
To confirm the presence of neoplastic cells, selected tissues
were excised from the mice at necropsy and were preserved
in 10% formalin solution (Sigma) immediately after ex vivo
imaging. Tissues were prepared for histopathology (paraffin
preparation, sectioning, and hematoxylin and eosin staining)
and analyzed by subsequent microscopic evaluation by IDEXX
Veterinary Services (West Sacramento, CA, USA).
Statistical analyses
The mean bioluminescence (photons/s), tumor volume, and
corresponding standard errors of the mean were determined
for each experiment. Regression plots were used to describe
the relationship between bioluminescence and cell number
and tumor volume; R2 values are reported to assess the quality
of the regression model.
Results
Stable luciferase expression of MDA-MB-231-luc 
derivative cell lines
Parental MDA-MB-231 cells were transfected with a plasmid
encoding firefly luciferase, and several stable clones were
selected in vitro. A resulting bioluminescent cell line with rea-
sonable bioluminescence in vitro (D3) was isolated and
injected into the mammary fat pad of nude mice. Following 12
weeks of growth in vivo, tumor cells were harvested from a pri-
mary tumor and re-propagated in vitro to produce the MDA-
MB-231 subclone line D3H1. These cells were injected once
more into the mammary fat pad of mice to yield a second cell
line, D3H2LN, harvested from a lymph node metastasis of a
D3H1 mammary tumor.
To determine whether prolonged growth in vivo affected bio-
luminescence of the D3H1 or D3H2LN cells over time relative
to the original D3 luciferase-expressing line, serial dilutions
from cell cultures of each were imaged and compared in vitro
(Fig. 1). The mean photon emissions ranged from approxi-
mately 100 to 208 photons/s per cell, and we found no
decrease in bioluminescence as the MDA-MB-231 luciferase-
expressing subclones were passaged through animals. The
D3H2LN cells were in fact slightly brighter in vitro than the
D3H1 or original D3 cells. The data indicate that the level of
luciferase expression remained relatively stable for up to 12
weeks of tumor growth for the D3H1 cells, and after an addi-
tional 12 weeks of in vivo growth for the D3H2LN cells.
Enhanced tumorigenicity of D3H1 and D3H2LN cell lines 
in the mammary fat pad
The mammary tumor growth rates of the two luciferase-
expressing derivatives were compared with the nonglowing
parental MDA-MB-231 cells (Fig. 2a). Mean external caliper
measurements of mammary tumors indicated that the D3H1
cells grew at a slightly faster rate than did the original parental
cells. The D3H2LN cells exhibited a dramatic increase in
tumor growth relative to both the D3H1 and the parental cells
in vivo. By 5 weeks of growth in nude mice, the D3H2LN
tumors had reached a volume more than two to seven times
larger than the tumors of the other cell lines at 8 weeks after
injection (Fig. 2a). Similar results were found with nude-beige
mice (Fig. 2b), although tumor growth in general was slower
for both D3H1 and D3H2LN cells in these experiments as
compared with the rates in nude mice.Breast Cancer Research    Vol 7 No 4    Jenkins et al.
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The growth of D3H1 and D3H2LN mammary tumors in nude
or nude-beige mice was also monitored in vivo by biolumines-
cent imaging. The mean photons emitted from the tumors over
time in each cohort were compared with the corresponding
tumor volumes of the same animals. Bioluminescent data cor-
related with tumor volume, with overall R2 values of 0.95–0.98
(Fig. 2a, b). The only exception occurred at the final time points
for the D3H2LN cells in nude mice, when the extremely fast
growing tumors at weeks 4 and 5 continued to increase in vol-
ume but the bioluminescence leveled off or decreased. The
developing necrotic cores in these tumors, confirmed by post-
mortem histological analysis (histology data not shown), pre-
sumably contributed to the diminished photon emission at the
later time points.
Spontaneous metastasis from primary mammary fat pad 
tumors
Mice with D3H1 and D3H2LN mammary tumors were evalu-
ated in vivo for spontaneous metastasis to the lungs or tho-
racic lymph nodes by shielding the bright primary tumors
growing in the abdominal fat pad and reimaging the thorax of
each animal. Representative images over time from a nude-
beige mouse with D3H2LN tumors are presented in Fig. 3. A
summary of the data from nude and nude-beige mice with
D3H1 or D3H2LN tumors is presented in Table 1.
Similar to the D3H2LN tumor volume data shown in Fig. 2b,
D3H2LN mammary tumor bioluminescence started to
increase about 4 weeks after cell injection in nude-beige mice
(Fig. 3, upper panels). Metastatic signals also appeared at that
time in the right axillary region in 33% (2/6) of the mice, indi-
cating spontaneous thoracic metastasis on the same side of
the animal as the developing distal primary tumor. Subsequent
thoracic images demonstrated an incremental increase in met-
astatic growth over time, and by week 6 all six mice had devel-
oped right axillary signals. Also at this time point, half of the
mice exhibited additional metastatic signals in the left axilla,
and by the end of the experiment all animals had developed
bilateral thoracic metastases (Fig. 3).
The location and size of the in vivo bioluminescent signals sug-
gested lymph node metastasis, and so the brachial and axillary
lymph nodes of all mice were excised at necropsy, imaged ex
vivo, and preserved for histological evaluation. Lung lobes
were also included in the analysis as an alternative site for
metastasis. Figure 3 (middle panel) shows the ex vivo images
of the lymph nodes and lung lobes from a representative
mouse. Brachial lymph nodes in all mice and lung lobes in
67% (4/6) of the cohort were bioluminescent ex vivo. The
brighter ex vivo signal of the right brachial lymph nodes com-
pared with the left lymph nodes correlated with the relatively
higher intensity observed in vivo in the right thoracic area at
the final time points. In the lung lobes, the ex vivo signal was
at least 10-fold lower than the brachial lymph nodes, suggest-
ing a much lower tumor burden in lungs than in lymph nodes.
Subsequent histological evaluation confirmed extensive and
pervasive tumor growth in the brachial lymph nodes and lim-
ited, sporadic micrometastasis in the lung lobes (Fig. 3, lower
panels). Selected axillary lymph nodes, which were negative
for bioluminescence ex vivo, were also found to be negative by
histological examination (data not shown).
Tumor growth and metastasis of D3H2 tumors versus 
D3H2LN tumors
The mammary tumor take rate was lower and metastatic tumor
growth was slower in studies with D3H1 cells than in those
with D3H2LN cells. Table 1 shows the results for both nude
and nude-beige mice. Metastatic spread to lymph nodes was
also more limited in mice with D3H1 primary tumors, and
spontaneous metastasis to both right and left brachial lymph
nodes was rare or nonexistent. In contrast, all mice with
D3H2LN mammary tumors developed right lymph node
Figure 1
In vitro bioluminescence of MDA-MB-231 sublines D3, D3H1 and D3H2LN In vitro bioluminescence of MDA-MB-231 sublines D3, D3H1 and D3H2LN. Cells from each subline were serially diluted in duplicate wells from 
4000 to 8 cells/well. Luciferin substrate was added to each well and the plate was imaged to obtain photons/s per cell. Wells with media (no cells) 
or cells alone (no luciferin) were included as controls. The range of bioluminescence for each subline represents data collected from two to three 
experiments.
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metastasis, and detection of bilateral spread was found in
100% of the nude beige mice. The detection of
micrometastasis to lung lobes was observed in 38–67% of the
mice with D3H2LN mammary tumors, whereas lung microme-
tastasis was nearly absent in mice that had D3H1 mammary
tumors. Overall, nude-beige mice had higher frequencies of
lung or lymph node metastasis than did nude mice, regardless
of the tumor cell type used in the study.
Detection of metastases following intracardiac injection 
of MDA-MB-231-luc cells
We used a nonsurgical intracardiac injection of D3H1 or
D3H2LN cells to compare experimental metastasis after sys-
temic circulation of cells. Mice were imaged immediately after
injection of cells and once a week thereafter. Ventral and dor-
sal images of a representative nude mouse injected with
D3H2LN cells are shown in Fig. 4. Animals with successful int-
racardiac injection (8/12) on day zero showed low level, wide-
spread bioluminescence minutes after the injection. Within 2
weeks, localized bioluminescent signals indicating metastasis
began to appear at a few sites in each animal. By 3–4 weeks
after injection, all eight mice exhibited clear indications of
tumor growth at multiple sites in the head, thorax, abdomen,
legs, or spine. None of these tumors was superficially obvious
or palpable.
Ex vivo imaging was conducted with 17–20 different tissues
excised from each mouse after the final in vivo imaging ses-
sion at week 5. These tissues included untrimmed specimens
of bones (jaw, skull, ribs, scapulae, clavicles, femur/tibia,
Figure 2
Mammary tumor growth is enhanced in D3H1 and D3H2LN bioluminescent sublines of MDA-MB-231 cells Mammary tumor growth is enhanced in D3H1 and D3H2LN bioluminescent sublines of MDA-MB-231 cells. Cells were injected into the mammary 
fat pad of (a) nude or (b) nude-beige mice, and mean tumor volumes were determined by caliper measurements over time. The tumors from the bio-
luminescent sublines D3H1 and D3H2LN were also monitored using in vivo imaging, and the correlation between mean photons/s and mean tumor 
volume are indicated as R2 values.
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Figure 3
D3H2LN mammary tumors grow rapidly and produce bilateral lymph node metastasis D3H2LN mammary tumors grow rapidly and produce bilateral lymph node metastasis. Bioluminescent D3H2LN cells were injected into nude-beige 
mice, and tumor growth and metastasis were monitored over time in vivo. Data for a representative mouse are shown. Tumor take rate was high (6/
8 mice) and lymph node metastasis to both the right and left thoracic areas was detected by week 9 in all mice with mammary tumors (upper pan-
els). Ex vivo images of excised brachial lymph nodes and lung lobes are shown (middle panels). Histological analysis of the same tissues confirmed 
perfuse metastasis to the lymph nodes and isolated micrometastasis to the lung lobes (lower panels).
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vertebrae) along with isolated lungs, lymph nodes, salivary
glands, and soft tissues such as brain, liver, pancreas, uterus,
kidney and adrenals. In general, ex vivo images corroborated
widespread metastasis in all mice injected with D3H2LN cells
(Table 2). Representative ex vivo images of skeletal and brain
metastasis are shown in Fig. 5, along with views of their corre-
sponding histology sections. In all mice (8/8) metastasis to
some type of bone-associated tissue was detected by ex vivo
imaging, with frequencies greater than 50% for spine, skull,
scapula, leg, or clavicle. A majority of animals injected with
D3H2LN cells exhibited bioluminescent evidence of metasta-
sis to the rib cage (8/8), brain (7/8), lungs (6/8), and thoracic
lymph nodes (5/8). Less frequent metastasis (2–4/8) was
observed  ex vivo in the liver, pancreas, kidney/adrenals,
uterus, heart, or salivary glands.
The panel of tissues examined by ex vivo imaging was also
evaluated by histological analysis in two of the eight mice that
presented with widespread metastasis from D3H2LN cells.
Tumor lesions were sporadic and small in many of the tissues
and some had to be re-sectioned and evaluated two or three
times in order to locate what often was described as a few
micrometastases per section. Nevertheless, metastasis was
identified by microscopic examination in the majority of the tis-
sues from at least one of the two mice sampled (Table 2, Fig.
5). In nearly all the lungs and rib sections, micrometastases
were detected on the pleural surface, and not within the lung
parenchyma or bone proper. It was generally not possible to
detect micrometastasis to the larger soft organs by histology
in the tissues from the two mice examined, although ex vivo
imaging detected low levels of bioluminescence (data not
shown).
Mice injected with D3H1 cells exhibited widespread metasta-
sis in vivo after intracardiac injection but with lower frequency
at each site compared with animals injected with the D3H2LN
cells (Table 2). The first in vivo indication of metastasis in any
of the D3H1 cohort occurred at week 5, which was 3 weeks
Figure 4
Multiple metastases detected in vivo following intracardiac injection of D3H2LN cells Multiple metastases detected in vivo following intracardiac injection of D3H2LN cells. Ventral (upper panels) and dorsal (lower panels) images taken 
over time from a representative nude mouse injected with D3H2LN cells are shown. Pseudocolor scale bars were consistent for all images of ventral 
or dorsal views in order to show relative changes at metastatic sites over time.
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later than in animals injected with the same number of
D3H2LN cells (Fig. 5), and it took 10 weeks for metastasis to
develop in a majority of animals injected with D3H1 cells ver-
sus 5 weeks for mice injected with D3H2LN cells. Although
metastasis was confirmed by histology in most of the tissue
samples from animals with D3H1 cells, isolated micrometasta-
sis was frequently found associated with attendant muscle or
fat rather than within the organs themselves (data not shown).
Discussion
Bioluminescent imaging has been used to detect primary can-
cer growth and metastasis in a growing number of animal
models [14-20]. In xenograft tumor models, human cell lines
expressing luciferase have permitted studies that yield real-
time, noninvasive monitoring of tumor sites in the same cohort
of animals over time. This study is the first application of in vivo
bioluminescent imaging to monitor breast cancer tumor
growth in animals and to detect spontaneous metastasis of
tumor cells from the mammary fat pad to lymph nodes and
lungs. The luciferase-expressing subclones of MDA-MB-231
characterized in this report also produced multiple metastases
at high frequencies to clinically relevant tissues such as bone
and brain following intracardiac injection of cells. With the abil-
ity to produce lymph node and lung metastasis from primary
tumors and widespread metastasis after intracardiac injection,
the D3H1 and D3H2LN subclones of MDA-MB-231 cells fully
mimic the range of breast cancer development in humans.
Previous studies have noted lymph node and lung metastasis
from parental MDA-MB-231 mammary tumors in mice but
have largely relied on postmortem histology or PCR to docu-
ment the presence of limited metastasis, especially to the
lungs, from MDA-MB-231 primary tumors [4]. Our imaging
experiments yielded similar findings but they did not require
time consuming tissue processing and analysis. The low biolu-
minescence of the micrometastasis to the lung from mammary
Table 1
Mammary fat pad model tumor take and metastasis
Cell line Experimental parameters Detected metastases
Mouse strain n Take rate End-point (weeks) LN in vivo Lung ex vivo
D3H1 Nude 9, 10 40–78% 8–13 75–86% R, 0% L 0–16%
Nude-beige 6 66% 13 67% R, 16% L 0%
D3H2LN Nude 9, 8 89–100% 5 100% R, 0% L 38%
Nude-beige 8 75% 9 100% R, 100% L 67%
L, left; LN, lymph node; R, right.
Table 2
Ex vivo detection of metastasis after intracardiac injection (nude mice)
H2LN (n = 8) D3H1 (n = 5)
Experimental end-point Week 5 Week 10
Skeletal metastasis 8/8 4/5
Spine 88%a 60%a
Skull 75%a 40%a
Scapula 75% 40%a
Femur/tibia 63%a 0%a, b
Clavicle 50% 0%
Upper/lower jaw 13–23% ND 0–20%
Ribs and associated tissues 8/8a 4/5a
Brain 7/8a 2/5a
Lungs 6/8a 2/5a
Lymph nodes (axillary/brachial) 5/8a 2/5
Other soft tissues (heart, liver, pancreas, kidney, adrenals, uterus, salivary gland) 4/8 2/5
aMetastasis confirmed by histology in at least one animal sample. bThree out of five mice exhibited in vivo leg signal, and metastasis was confirmed 
by histology. ND, tissue not analyzed by histology.Available online http://breast-cancer-research.com/content/7/4/R444
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Figure 5
Ex vivo and histological data confirm metastases from intracardiac injection of D3H2LN cells Ex vivo and histological data confirm metastases from intracardiac injection of D3H2LN cells. Representative data from selected tissues from two 
mice that were evaluated by both ex vivo imaging and subsequent histological analysis are shown.
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tumors was detected immediately in excised tissues by ex vivo
analysis. The more pervasive lymph node metastasis was
detected in both live animals over time and by ex vivo exami-
nation. Subsequent microscopic evaluation of the metastatic
tissues initially identified as positive or negative by biolumines-
cent imaging was used to confirm tumor spread and allowed
precise localization and sizing of lesions at the cellular level.
MDA-MB-231 luciferase-expressing cells were injected in the
mammary fat pad of mice and passaged one or two times in
vivo  to generate a more robust xenograft model of human
breast cancer with enhanced primary tumor growth and
subsequent metastasis. In evaluating the photon emission of
these cell lines, we found no decrease in bioluminescence
between the D3H1 cells, D3H2LN cells, and the original
unpassaged D3 subclone from the parental MDA-MB-231
cells, despite 12 weeks of tumor growth for D3H1 cells and
24 weeks of accumulated in vivo growth time for the D3H2LN
line. Additionally, the D3H1 and D3H2LN cell lines maintained
consistent levels of bioluminescence in vitro for up to 2
months or approximately eight to 10 passages in culture (data
not shown). These data demonstrate remarkable long-term
stability of luciferase expression after multiple rounds of in vivo
growth and continuous periods of in vitro culturing.
The intracardiac injection model is used to generate wide-
spread arterial dissemination of tumor cells by bypassing the
lungs in order to seed cells to various organs. This method has
been employed with luciferase-positive MDA-MB-231 deriva-
tive cell lines that were selected for enhanced in vivo metasta-
sis to bone [10,13]. The metastatic spread of these cells after
intracardiac injection was primarily to bone sites, with limited
visceral metastasis to the adrenals or pancreas. Our D3H1
and D3H2LN sublines expand the utility of such models by
producing consistent metastatic lesions to brain and various
visceral organs as well as skeletal sites following intracardiac
injection. In previous reports researchers compared biolumi-
nescent imaging with radiometric measurements of bone
metastasis, and found in vivo imaging to be the faster and
more sensitive detection method [10]. Similarly, our intracar-
diac experiment compared imaging with histological examina-
tion and showed that, in many cases, tissues that had been
found to be positive by in vivo or ex vivo imaging required mul-
tiple rounds of sectioning and histology to identify the
micrometastasis.
In both nude and nude-beige mice, the D3H2LN tumors pro-
duced a faster rate of tumor growth in the mammary fat pad as
well as enhanced spontaneous metastasis to the lymph nodes
and lungs compared with the D3H1 cells (Fig. 2 and Table 1).
The D3H2LN cells also exhibited higher frequencies of metas-
tasis to bone, brain, lungs, and soft tissues after intracardiac
injection (Table 2). Taken together, these findings suggest a
more invasive phenotype in the D3H2LN cells and demon-
strate an enhanced utility in animal metastasis studies. We did
find that the rapid growth of D3H2LN cells in some mammary
fat pad experiments created necrotic tumors that showed a
decrease in bioluminescent signal in vivo at later time points,
despite an incremental increase in tumor volume (Fig. 2a). A
similar disparity between volume measurements and biolumi-
nescence with larger tumors was reported in a study using
subcutaneous tumors of human prostate cells expressing luci-
ferase [11]. Here, the authors noted that tumor volume
became static after treatment of animals, while a drop in biolu-
minescence of the same tumors indicated a tumoricidal effect
on cells that was subsequently confirmed by histology.
Conclusion
The bioluminescent stability of the D3H1 and D3H2LN cell
lines, coupled with their enhanced tumorigenicity and wide-
spread metastatic potential, provides a sensitive in vivo model
system for preclinical assessment of breast cancer growth,
dissemination, and response to anticancer therapies.
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